Merrimack
Feb 22, 2017

Merrimack Announces Timing of Fourth Quarter 2016 Investor Conference Call

CAMBRIDGE, Mass., Feb. 22, 2017 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) today announced that the company will host its Fourth Quarter 2016 investor conference call and webcast at 8:30 a.m., Eastern time, on Wednesday, March 1.   

The call will cover an update on Merrimack's recent progress as well as a summary of fourth quarter and full year 2016 financial results. A press release detailing the information to be discussed on the call will be issued the morning of Wednesday, March 1. Investors and the general public are invited to listen to the call by dialing (877) 564-1301 (domestic) or (224) 357-2394 (international) five minutes prior to the start of the call and providing the passcode 71929949.

A listen-only webcast of the call will be available in the Investors section of Merrimack's website, investors.merrimack.com, and a replay of the call will be archived there for six weeks.

About Merrimack

Merrimack Pharmaceuticals is a biopharmaceutical company based in Cambridge, Massachusetts. More information can be found at www.merrimack.com.   

Forward-Looking Statements

Any statements in this press release about future expectations, plans and prospects for Merrimack constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, as amended. Actual results may differ materially from those indicated by such forward-looking statements. Merrimack anticipates that subsequent events and developments will cause its views to change. However, while Merrimack may elect to update these forward-looking statements at some point in the future, Merrimack specifically disclaims any obligation to do so.

CONTACT:

Geoffrey M. Grande, CFA
617-441-7602
ggrande@merrimack.com

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/merrimack-announces-timing-of-fourth-quarter-2016-investor-conference-call-300411855.html

SOURCE Merrimack Pharmaceuticals, Inc.

News Provided by Acquire Media